{"schema_version":"secwatch.filing_event.v1","accession":"0001689548-25-000062","form_type":"8-K","ticker":"PRAX","cik":"0001689548","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2025-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.345767+00:00","generated_at":"2026-05-22T22:54:38.270928+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Praxis Precision reports sustained seizure reduction with relutrigine, announces Phase 3 trial design","bullets":["Updated EMBOLD open-label data (n=12) show sustained seizure reduction and increased seizure-free periods through 11 months of relutrigine treatment in SCN2A/SCN8A DEEs.","Announced EMERALD Phase 3 trial design: randomized, placebo-controlled, 160 patients aged 2–65 years, 16-week treatment period.","Plans to nominate development candidate for PRAX-100, an antisense oligonucleotide targeting SCN2A loss-of-function in autism, in mid-2025.","Corporate presentation furnished as Exhibit 99.1 includes program updates provided at May 2, 2025 investor event."],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-25-000062","json":"https://secwatch.observer/filing/0001689548-25-000062.json","markdown":"https://secwatch.observer/filing/0001689548-25-000062.md","text":"https://secwatch.observer/filing/0001689548-25-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000062/0001689548-25-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954825000062/prax-20250502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T22:54:38.270928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}